0LC7.LSE Syros Pharmaceuticals, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0LC7.LSE undervalued?
Graham numberThe Graham number of Syros Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Syros Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for Syros Pharmaceuticals, Inc. yet.
Syros Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patie…
Full company profileFinancial statements of Syros Pharmaceuticals, Inc. are not available yet.
Syros Pharmaceuticals, Inc. dividends
Syros Pharmaceuticals, Inc. has not paid dividends in the last 3 fiscal years.
Last stock split: 0.1:1 on Sep 19, 2022.
Who owns Syros Pharmaceuticals, Inc.
Ownership data of Syros Pharmaceuticals, Inc. is not available yet.
Syros Pharmaceuticals, Inc. company profile
- Company name
- Syros Pharmaceuticals, Inc.
- Ticker
- 0LC7.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 68
- Fiscal year end
- December
- Address
- 35 CambridgePark Drive, Cambridge, MA, United States, 02140
- Phone
- 617 744 1340
- Website
- syros.com
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Syros Pharmaceuticals, Inc. management
3- Dr. James E. Bradner M.D.Founder · born 1972
- Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory Board
- Matthew FosterChief Restructuring Officer